{"nctId":"NCT04206020","briefTitle":"Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome","startDateStruct":{"date":"2019-12-20","type":"ACTUAL"},"conditions":["Dry Eye Syndrome"],"count":610,"armGroups":[{"label":"Placebo Comparator: SkQ1 Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: SkQ1 Vehicle Solution"]},{"label":"SkQ1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: SkQ1 Ophthalmic Solution"]}],"interventions":[{"name":"SkQ1 Vehicle Solution","otherNames":["Vehicle for SkQ1"]},{"name":"SkQ1 Ophthalmic Solution","otherNames":["Visomitin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be at least 18 years of age;\n* Provide written informed consent;\n* Have a subject reported history of dry eye;\n* Have a history of use of eye drops for dry eye symptoms;\n* Ocular Discomfort;\n* Schirmer's Test score;\n* Have corneal fluorescein staining ;\n* Have lissamine green conjunctival Staining;\n* Have a conjunctival redness;\n\nExclusion Criteria:\n\n* Have been previously exposed to previous SkQ1 Ophthalmic Solution treatment;\n* Have any clinically significant slit lamp findings at Visit 1;\n* Be diagnosed with an ongoing ocular infection or active ocular inflammation at Visit 1;\n* Have had any ocular and/or lid surgeries within 6 months of Visit 1 or any planned over the study period;\n* Have an uncontrolled systemic disease;\n* Be a woman who is pregnant, nursing or planning a pregnancy;\n* Be a woman of childbearing potential who is not using an acceptable means of birth control;\n* Have a known allergy and/or sensitivity to the study drug or its components;\n* Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;\n* Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1;","healthyVolunteers":false,"sex":"ALL","genderBased":true,"genderDescription":"self-representation","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Discomfort Scale","description":"Change of Ocular Discomfort Scale, scale ranged from 0 to 4 with 0 = No Discomfort and 4 = Constant Discomfort.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.36"},{"groupId":"OG001","value":"-0.6","spread":"1.34"}]}]}]},{"type":"PRIMARY","title":"Conjunctival Fluorescein Staining","description":"Change of Conjunctival Fluorescein Staining (sum of temporal and nasal regions), scale in each region ranged from 0 to 4 with 0 = No Staining and 4 = Confluent Staining","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.63","spread":"1.087"},{"groupId":"OG001","value":"-0.69","spread":"1.150"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":306},"commonTop":["Instillation site pain","Visual acuity reduced"]}}}